[In vitro activity of delafloxacin against clinical isolates of carbapenem-resistant Pseudomonas aeruginosa in a stage prior to the clinical use of this drug].
作者信息
García-Rivera C, Navarro M, Parra M, Sánchez Bautista A, Gómez I, Ventero M P, Rodríguez J C
机构信息
María-Paz Ventero, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Av. Pintor Baeza 12, 03010. Alicante, Spain.
出版信息
Rev Esp Quimioter. 2024 Feb;37(1):104-105. doi: 10.37201/req/080.2023. Epub 2023 Dec 22.
Abstract
摘要
相似文献
1
[In vitro activity of delafloxacin against clinical isolates of carbapenem-resistant Pseudomonas aeruginosa in a stage prior to the clinical use of this drug].在德拉氟沙星临床使用前阶段，其对耐碳青霉烯类铜绿假单胞菌临床分离株的体外活性
Rev Esp Quimioter. 2024 Feb;37(1):104-105. doi: 10.37201/req/080.2023. Epub 2023 Dec 22.
2
Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.耐左氧氟沙星铜绿假单胞菌临床分离株中氟喹诺酮类和碳青霉烯类药物敏感性的特征分析
Chemotherapy. 2005 May;51(2-3):70-5. doi: 10.1159/000085612. Epub 2005 May 4.
3
Characterization of acquired β-lactamases in and quantification of their contributions to resistance.研究获得性β-内酰胺酶的特性及其对耐药性的贡献。
Microbiol Spectr. 2024 Oct 3;12(10):e0069424. doi: 10.1128/spectrum.00694-24. Epub 2024 Sep 9.
4
Carbapenemase -producing Pseudomonas aeruginosa isolates from Turkey: first report of P. aeruginosa high-risk clones with VIM-5- and IMP-7-type carbapenemases in a tertiary hospital.土耳其产碳青霉烯酶铜绿假单胞菌分离株：三级医院中发现具有 VIM-5 和 IMP-7 型碳青霉烯酶的高风险克隆的铜绿假单胞菌的首次报告。
Diagn Microbiol Infect Dis. 2021 Jan;99(1):115174. doi: 10.1016/j.diagmicrobio.2020.115174. Epub 2020 Aug 12.
5
Determination of extended spectrum beta-lactamases, metallo-beta-lactamases and AmpC-beta-lactamases among carbapenem resistant Pseudomonas aeruginosa isolated from burn patients.从烧伤患者分离出的耐碳青霉烯类铜绿假单胞菌中检测超广谱β-内酰胺酶、金属β-内酰胺酶和AmpCβ-内酰胺酶
Burns. 2014 Dec;40(8):1556-61. doi: 10.1016/j.burns.2014.02.010. Epub 2014 Apr 22.
6
Distribution of Pseudomonas-Derived Cephalosporinase and Metallo-β-Lactamases in Carbapenem-Resistant Pseudomonas aeruginosa Isolates from Korea.韩国碳青霉烯耐药铜绿假单胞菌分离株中假单胞菌衍生头孢菌素酶和金属β-内酰胺酶的分布
J Microbiol Biotechnol. 2015 Jul;25(7):1154-62. doi: 10.4014/jmb.1503.03065.
7
Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.头孢他洛滨-他唑巴坦对产碳青霉烯酶非产碳青霉烯酶耐药铜绿假单胞菌的活性及相关耐药机制。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01970-17. Print 2018 Jan.
8
Carbapenem inactivation: a very affordable and highly specific method for phenotypic detection of carbapenemase-producing Pseudomonas aeruginosa isolates compared with other methods.碳青霉烯灭活：与其他方法相比，一种用于产碳青霉烯酶铜绿假单胞菌分离株表型检测的经济高效且高度特异的方法。
J Chemother. 2017 Jun;29(3):144-149. doi: 10.1080/1120009X.2016.1199506. Epub 2016 Jul 22.
9
Impact of meropenem exposure on fluoroquinolone and carbapenem resistance in Pseudomonas aeruginosa infection in inpatients in a Japanese university hospital: Insights into oprD mutations and efflux pump overexpression.美罗培南暴露对日本大学医院住院患者铜绿假单胞菌感染中氟喹诺酮和碳青霉烯耐药性的影响：对oprD突变和外排泵过表达的见解
J Glob Antimicrob Resist. 2025 Mar;41:163-168. doi: 10.1016/j.jgar.2024.12.029. Epub 2025 Jan 14.
10
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.德国碳青霉烯类耐药铜绿假单胞菌的传播及其对头孢他啶-他唑巴坦的药敏情况。
Int J Antimicrob Agents. 2020 Jun;55(6):105959. doi: 10.1016/j.ijantimicag.2020.105959. Epub 2020 Apr 20.
本文引用的文献
1
Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria.西班牙传染病和临床微生物学会（SEIMC）关于耐碳青霉烯类革兰氏阴性菌引起的感染的诊断和抗菌治疗的共识文件摘要。
Enferm Infecc Microbiol Clin (Engl Ed). 2023 Jun-Jul;41(6):360-370. doi: 10.1016/j.eimce.2022.06.014. Epub 2022 Dec 13.
2
Delafloxacin-Capped Gold Nanoparticles (DFX-AuNPs): An Effective Antibacterial Nano-Formulation of Fluoroquinolone Antibiotic.地拉氟沙星包覆金纳米颗粒（DFX-AuNPs）：一种有效的氟喹诺酮类抗生素抗菌纳米制剂。
Materials (Basel). 2022 Aug 18;15(16):5709. doi: 10.3390/ma15165709.
3
Carbapenemase-producing -an emerging challenge.产碳青霉烯酶 - 新出现的挑战。
Emerg Microbes Infect. 2022 Dec;11(1):811-814. doi: 10.1080/22221751.2022.2048972.
4
Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline.德拉氟沙星、非那沙星和扎博沙星：抗生素研发中的新型氟喹诺酮类药物。
Antibiotics (Basel). 2021 Dec 8;10(12):1506. doi: 10.3390/antibiotics10121506.
5
New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship.多药耐药革兰氏阴性菌的新药：是时候进行管理了。
Drugs. 2019 May;79(7):705-714. doi: 10.1007/s40265-019-01112-1.
6
Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria.治疗多重耐药革兰氏阴性菌感染的研究性药物。
Expert Opin Investig Drugs. 2018 Apr;27(4):325-338. doi: 10.1080/13543784.2018.1460354. Epub 2018 Apr 10.
7
What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone.旧药新用：德拉沙星，一种新型氟喹诺酮类药物。
Pharmacotherapy. 2018 Jan;38(1):108-121. doi: 10.1002/phar.2050. Epub 2017 Nov 23.
Zotero 插件